GlobeImmune files for $69 million IPO to fund cancer/infection immunotherapies
This article was originally published in Scrip
GlobeImmune wants to raise $69 million in an initial public offering to fund development of its oncology and infectious disease immunotherapies before it runs out of cash around the end of 2012. The company did not indicate how many shares it will sell, or at what price.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.